ArticleAvicenna journal of phytomedicine2026
The hepatoprotective impacts of
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Type 1 Diabetes (T1D) induces several consequences including hepatic damage resulting from oxidative stress and inflammation. The Nrf2/Keap1 pathway is crucial in oxidative stress signaling, and its modifications significantly influence health and illness. In this study, rats with T1D were used to test Materials and Methods: Twenty-one male Wistar rats were assessed. Three groups-control (healthy rats), diabetes (received STZ), and diabetes with drug-were allocated at random to the rats. The CC fruits extract was administered to diabetic rats via gavage for 40 days. Oxidative stress indicators, including malondialdehyde (MDA), total antioxidant capacity (TAC), and superoxide dismutase (SOD), were determined. The ELISA method quantified liver cytokines, whereas western blotting evaluated the Nrf2/Keap1 pathway. Results: The administration of CC in the Diabetes+Drug group dramatically reduced MDA levels while enhancing SOD activity and TAC levels in the liver. Following CC administration, Tumor necrosis factor alpha (TNF-α) levels decreased while rats with diabetes had higher amounts of interleukine-10 (IL-10) in their liver tissue. The CC administration could regulate the Nrf2/Keap1 pathway. Conclusion: This study concluded that a daily administration of 200 mg/kg CC for 40 days can enhance liver function in diabetic subjects by controlling the Nrf2/Keap1 pathway and reducing oxidative stress and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.